This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Servier, n-Lorem Foundation...
Business research collaboration

Servier, n-Lorem Foundation collaborate on ASO

Analysis based on 9 articles · First reported Jun 10, 2026 · Last updated Jun 10, 2026

Sentiment
70
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This collaboration is expected to positively impact the pharmaceutical and biotechnology markets by advancing precision medicine for rare neurological disorders. It could lead to new treatment options, potentially increasing revenue streams for companies involved in the development and commercialization of these therapies.

Pharmaceuticals Biotechnology
Event Summary

Laboratoires Servier and Foundation have announced a multi-target research collaboration to develop antisense oligonucleotide (ASO) therapeutic approaches for rare and devastating neurodevelopmental disorders. The partnership combines Foundation's ASO technology platform with Laboratoires Servier's R&D expertise to engineer preclinical candidates that Laboratoires Servier will advance into clinical development. This initiative aims to extend precision genetic medicine to patients with rare neurological disorders who currently lack approved treatment options, aligning with Laboratoires Servier's 2030 ambition to develop innovative treatments for conditions like refractory epilepsy, autism spectrum disorders, and leukodystrophies. Nitza Thomasson of Laboratoires Servier and Stanley T. Crooke of Foundation both expressed enthusiasm for the partnership's potential to accelerate research and deliver meaningful therapies.

Entities Involved
priv
Laboratoires Servier
Laboratoires Servier is strengthening its commitment to rare neurological diseases and advancing its 2030 ambition by partnering with Foundation to develop innovative treatments.
Importance 90.0 Sentiment 70.0
per
Nitza Thomasson
Nitza Thomasson, Global Head of R&D Neurology at Laboratoires Servier, expressed pride in the partnership and its potential to accelerate new approaches for patients.
Importance 30.0 Sentiment 0.0
per
Stanley T. Crooke
Stanley T. Crooke, Founder, Chairman and CEO of Foundation, welcomed Laboratoires Servier as a partner, highlighting the mutual benefits for patients with rare diseases.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.